COLORADO SPRINGS, Colo., Oct. 24 /PRNewswire-FirstCall/ -- Spectranetics Corporation today announced its products were used in several live case sessions at the Transcatheter Cardiovascular Therapeutics (TCT) convention, held October 16-21 in Washington, D.C., and attended by more than 9,000 physicians.
Among the six live case sessions featuring Spectranetics’ technology, two used the new CLiRpath(R) 2.5 Turbo catheter, and two cases demonstrated the Quick-Cross(R) catheter.
In a live case session from the Heart Center in Leipzig, Germany, Prof. Giancarlo Biamino, M.D. Ph.D successfully treated a 10 centimeter lesion in the superficial femoral artery (SFA) with the CLiRpath 2.5 Turbo catheter. The session spotlighted the 2.5 Turbo’s key improvements, including increased ablation, the “continuous on” lasing train capability and the hydrophilic coating for smoother catheter advancement. Prof. Biamino also pointed out the catheter’s ability to create a channel much larger than the 2.5 millimeter size of the catheter.
A live case by Gary Ansel, M.D., at Riverside Methodist Hospital in Columbus, Ohio, also utilized the CLiRpath 2.5 Turbo to treat a case of peripheral instent restenosis (ISR), which was followed by the placement of a covered stent. Dr. Ansel noted that this technique was his preferred method for treating ISR.
In live sessions using the Quick-Cross support catheter, one by Dr. Tony Das at the Presbyterian Heart Institute in Dallas, and the other by Dr. James Joye at El Camino Hospital in Mountain View, California, complex peripheral lesions were crossed, allowing for further intervention.
During several presentations at the conference, Quick-Cross was discussed as the “device of choice” for accessing and crossing tight and tortuous lesions.
“At this year’s TCT Conference there was a significant increase in laser technology as a recommended treatment for peripheral arterial disease,” said John G. Schulte, president and chief executive officer of Spectranetics. “It is clear our products are becoming a mainstream interventional tool for peripheral interventions, and the live case sessions and other presentations that featured our products demonstrated the advantages of laser in treating a wide range of indications, including critical limb ischemia, chronic total occlusions and thrombus-laden lesions.”
About Spectranetics
Spectranetics is a medical device company that develops, manufactures and markets single-use medical devices used in minimally invasive surgical procedures within the cardiovascular system in conjunction with its proprietary excimer laser system. Its CVX-300(R) excimer laser is the only system approved by the FDA for multiple cardiovascular procedures, including coronary atherectomy, and the removal of problematic pacemaker and defibrillator leads. Nearly all of the company’s FDA-approved and investigational applications have received Communautes Europeennes (CE) mark registration for marketing within Europe. In April 2004 Spectranetics obtained 510(k) clearance from the FDA for the laser-based treatment of patients suffering from total occlusions (blockages) in their leg arteries that are not crossable with a guide wire.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include increasing price and product competition, increased pressure on expense levels resulting from expanded marketing and clinical activities, uncertain success of the Company’s strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, the potential size of market opportunities associated with new products, market acceptance of new products or applications, product defects, price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company’s previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.
Spectranetics, CliRpath, QuickCross and CVX-300 are registered trademarks of The Spectranetics Corporation.
COMPANY CONTACT: INVESTOR & MEDIA CONTACTS: Spectranetics Corporation Lippert/Heilshorn & Associates, Inc. John Schulte, Bruce Voss Chief Executive Officer Don Markley Guy Childs, (310) 691-7100 Chief Financial Officer www.lhai.com (719) 633-8333 www.spectranetics.com
Spectranetics Corporation
CONTACT: John Schulte, Chief Executive Officer, or Guy Childs, ChiefFinancial Officer, both of Spectranetics Corporation, +1-719-633-8333; orInvestors or Media, Bruce Voss, or Don Markley, both of Lippert/Heilshorn &Associates, Inc., +1-310-691-7100, for Spectranetics Corporation
